Biosimilars For US Market May Be Able To Rely On EU-Licensed Reference Products
Executive Summary
Commissioner Scott Gottlieb says move could allow biosimilar sponsors to avoid anti-competitive efforts by brand sponsors in US.
You may also be interested in...
Biosimilar Sponsors Say Pharmacokinetic Bridging Studies Should Be The Exception, Not The Norm
US FDA guidance runs risk of creating de facto requirement for bridging studies when a biosimilar applicant seeks to use comparative data involving a foreign reference product, Novartis says; IGBA, AAM urge agency adopt a ‘global comparator’ approach that would eliminate the need for clinical bridging studies between US and foreign reference biologics.
Biosimilars: Is Small Dip In Development Indicative Of Sustained Downward Trend?
As US FDA sees dip in application development, experts offer contrasting assessments about future of biosimilars at AAM's GRx Biosims conference.
Biosimilars: Is Small Dip In Development Indicative Of Sustained Downward Trend?
As US FDA sees dip in application development, experts offer contrasting assessments about future of biosimilars at AAM's GRx Biosims conference.